Javier Cortes

New drug development

O. S. Zhukova, Guy Jerusalem, Robert Millham, 2012 .

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Peter Schmid, Rita Nanda, Hirdesh Uppal, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Jorge S. Reis-Filho, Josep Tabernero, J. Reis-Filho, 2013, Nature Reviews Clinical Oncology.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Chris Twelves, Fatima Cardoso, T. Delozier, 2011, The Lancet.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Salvatore Piscuoglio, Xavier de la Cruz, Jordi Rodon, 2015, Nature Communications.

Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer

Cristina Saura, J. Cortés, C. Saura, 2010 .

On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.

Lajos Pusztai, Christos Sotiriou, Stephen B. Fox, 2019, Journal of Clinical Oncology.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Antonio Marchetti, Keith T Flaherty, Dennie T Frederick, 2015, Nature Genetics.

LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

Peter Schmid, Rita Nanda, Sherene Loi, 2017 .

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

John W. Cassidy, James Hadfield, Carlos Caldas, 2016, Cell.